BioNTech SE Capital Reinvestment Ratio
BioNTech SE capital reinvestment ratio. BioNTech SE (22UA) has a Capital Reinvestment Ratio of 0.20x as of December 2025, meaning it reinvests 0% of its operating cash flow (€309.50 Million) in capital expenditures (€62.10 Million). Check 22UA capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of BioNTech SE (2021–2025)
Capital reinvestment ratio of BioNTech SE from 2021 to 2025. This chart tracks BioNTech SE's Capital Reinvestment Ratio across 5 annual periods. Also explore BioNTech SE (22UA) equity growth momentum to track the company's year-over-year net asset growth rate.
BioNTech SE Capital Reinvestment Ratio by Year (2021–2025)
BioNTech SE capital reinvestment ratio by year from 2021 to 2025. For the full cash flow conversion analysis, see BioNTech SE operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.64x | €456.00 Million | €749.00 Million | ▼ -24.6% |
| 2024 | 2.18x | €207.70 Million | €452.30 Million | ▲ +1558.0% |
| 2023 | 0.13x | €5.37 Billion | €705.50 Million | ▲ +390.9% |
| 2022 | 0.03x | €13.58 Billion | €363.30 Million | ▼ -81.3% |
| 2021 | 0.14x | €889.70 Million | €127.50 Million | — |